Human autoimmune diseases: A comprehensive update

Journal of Internal Medicine

Volumn 278, Issue 4, 2015, Pages 369-395

  Wang, Lifeng ^a   Wang, Fu Sheng ^a   Gershwin, M Eric ^b  

^a BEIJING 302 HOSPITAL   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoantibodies; Genetics and autoimmunity; Immune tolerance; Immunopathology

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOID CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STOCHASTIC MODEL; TARGET ORGAN; THYMUS; TISSUE INJURY; AUTOIMMUNE DISEASES; BIOLOGICAL MODEL; ENVIRONMENTAL EXPOSURE; FEMALE; GENETICS; MALE; TWINS;

AUTOIMMUNE DISEASES; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; MALE; MODELS, BIOLOGICAL; TWIN STUDIES AS TOPIC;

EID: 84941024816     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12395     Document Type: Review

References (259)

1. Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014; 48-49: 10-3.
2. Wang L, Wang FS, Chang C, Gershwin ME. Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis 2014; 34: 297-317.
3. Silverstein AM. Paul Ehrlich, archives and the history of immunology. Nat Immunol 2005; 6: 639.
4. Rose NR, Witebsky E. Studies on organ specificity. V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts. J Immunol 1956; 76: 417-27.
5. Salinas GF, Braza F, Brouard S, Tak PP, Baeten D. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin Immunol 2013; 146: 34-45.
6. Hang LM, Nakamura RM. Current concepts and advances in clinical laboratory testing for autoimmune diseases. Crit Rev Clin Lab Sci 1997; 34: 275-311.
7. Avrameas S, Selmi C. Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun 2013; 41: 46-9.
8. Panda S, Ding JL. Natural antibodies bridge innate and adaptive immunity. J Immunol 2015; 194: 13-20.
9. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-43.
10. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007; 29: 1-9.
11. Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819-31.
12. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010; 9: A387-94.
13. West J, Fleming KM, Tata LJ, Card TR, Crooks CJ. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am J Gastroenterol 2014; 109: 757-68.
14. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis 2014; doi: 10.1136/annrheumdis-2014-206334.
15. Cross M, Smith E, Hoy D et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014; 73: 1316-22.
16. Leung PS, Wang J, Naiyanetr P et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 2013; 41: 79-86.
17. Ulmanen I, Halonen M, Ilmarinen T, Peltonen L. Monogenic autoimmune diseases - lessons of self-tolerance. Curr Opin Immunol 2005; 17: 609-15.
18. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829-36.
19. Barrera MJ, Bahamondes V, Sepulveda D et al. Sjogren's syndrome and the epithelial target: a comprehensive review. J Autoimmun 2013; 42: 7-18.
20. Endo T, Kobayashi T. Immunization of mice with a newly identified thyroid-stimulating hormone receptor splice variant induces Graves'-like disease. J Autoimmun 2013; 43: 18-25.
21. Nagamine K, Peterson P, Scott HS et al. Positional cloning of the APECED gene. Nat Genet 1997; 17: 393-8.
22. Le Deist F, Emile JF, Rieux-Laucat F et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 1996; 348: 719-23.
23. Shah S, Wu E, Rao VK, Tarrant TK. Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma Rep 2014; 14: 462.
24. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15: 430-5.
25. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
26. Sollid LM, Pos W, Wucherpfennig KW. Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr Opin Immunol 2014; 31: 24-30.
27. Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 2013; 41: 25-33.
28. Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun 2013; 41: 1-5.
29. Hu X, Daly M. What have we learned from six years of GWAS in autoimmune diseases, and what is next? Curr Opin Immunol 2012; 24: 571-5.
30. Deitiker P, Atassi MZ. Non-MHC genes linked to autoimmune disease. Crit Rev Immunol 2012; 32: 193-285.
31. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011; 365: 1612-23.
32. Stanford SM, Bottini N. PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 2014; 10: 602-11.
33. Wiede F, Ziegler A, Zehn D, Tiganis T. PTPN2 restrains CD8(+) T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice. J Autoimmun 2014; 53: 105-14.
34. Kottyan LC, Zoller EE, Bene J et al. The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Hum Mol Genet 2015; 24: 582-96.
35. Muto A, Tashiro S, Nakajima O et al. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature 2004; 429: 566-71.
36. Itoh-Nakadai A, Hikota R, Muto A et al. The transcription repressors Bach2 and Bach1 promote B cell development by repressing the myeloid program. Nat Immunol 2014; 15: 1171-80.
37. Roychoudhuri R, Hirahara K, Mousavi K et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013; 498: 506-10.
38. Plagnol V, Howson JM, Smyth DJ et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet 2011; 7: e1002216.
39. Dubois PC, Trynka G, Franke L et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010; 42: 295-302.
40. Cooper JD, Smyth DJ, Smiles AM et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 2008; 40: 1399-401.
41. Franke A, McGovern DP, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-25.
42. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-9.
43. Jin Y, Birlea SA, Fain PR et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012; 44: 676-80.
44. Zhernakova A, Withoff S, Wijmenga C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat Rev Endocrinol 2013; 9: 646-59.
45. Quintero-Ronderos P, Montoya-Ortiz G. Epigenetics and autoimmune diseases. Autoimmune Dis 2012; 2012: 593720.
46. Fradin D, Le Fur S, Mille C et al. Association of the CpG methylation pattern of the proximal insulin gene promoter with type 1 diabetes. PLoS ONE 2012; 7: e36278.
47. Calabrese R, Zampieri M, Mechelli R et al. Methylation-dependent PAD2 upregulation in multiple sclerosis peripheral blood. Mult Scler 2012; 18: 299-304.
48. Kumagai C, Kalman B, Middleton FA, Vyshkina T, Massa PT. Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects. J Neuroimmunol 2012; 246: 51-7.
49. Lleo A, Liao J, Invernizzi P et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 2012; 55: 153-60.
50. Hu N, Qiu X, Luo Y et al. Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol 2008; 35: 804-10.
51. Young DA, Lakey RL, Pennington CJ et al. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 2005; 7: R503-12.
52. Yamamura Y, Motegi K, Kani K et al. TNF-alpha inhibits aquaporin 5 expression in human salivary gland acinar cells via suppression of histone H4 acetylation. J Cell Mol Med 2012; 16: 1766-75.
53. Xu WD, Pan HF, Li JH, Ye DQ. MicroRNA-21 with therapeutic potential in autoimmune diseases. Expert Opin Ther Targets 2013; 17: 659-65.
54. Qu Z, Li W, Fu B. MicroRNAs in autoimmune diseases. Biomed Res Int 2014; 2014: 527895.
55. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32: 189-94.
56. Wang Z, Zheng Y, Hou C et al. DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes. J Autoimmun 2013; 41: 50-9.
57. Colafrancesco S, Perricone C, Priori R, Valesini G, Shoenfeld Y. Sjogren's syndrome: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). J Autoimmun 2014; 51: 10-6.
58. Kivity S, Arango MT, Ehrenfeld M et al. Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review. J Autoimmun 2014; 51: 17-22.
59. Peng J, Narasimhan S, Marchesi JR, Benson A, Wong FS, Wen L. Long term effect of gut microbiota transfer on diabetes development. J Autoimmun 2014; 53: 85-94.
60. Bogdanos DP, Smyk DS, Invernizzi P et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 2013; 12: 726-40.
61. Cunningham MW. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol 2014; 33: 314-29.
62. Guilherme L, Oshiro SE, Fae KC et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001; 69: 5345-51.
63. Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol 2007; 32: 111-8.
64. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
65. James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001; 44: 1122-6.
66. Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology 1999; 53: 1367-8.
67. Amedei A, Bergman MP, Appelmelk BJ et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+ -adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003; 198: 1147-56.
68. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
69. Lehmann PV, Targoni OS, Forsthuber TG. Shifting T-cell activation thresholds in autoimmunity and determinant spreading. Immunol Rev 1998; 164: 53-61.
70. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155-7.
71. Duke RC. Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens. J Exp Med 1989; 170: 59-71.
72. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity-friends or foes? Trends Immunol 2009; 30: 409-14.
73. Draborg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013; 2013: 535738.
74. Abdelrahman HS, Selim HS, Hashish MH, Sultan LI. Epstein-Barr virus in multiple sclerosis. J Egypt Public Health Assoc 2014; 89: 90-5.
75. Morshed SA, Nishioka M, Saito I, Komiyama K, Moro I. Increased expression of Epstein-Barr virus in primary biliary cirrhosis patients. Gastroenterol Jpn 1992; 27: 751-8.
76. Root-Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep 2014; 14: 407.
77. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-60.
78. Dunne JL, Triplett EW, Gevers D et al. The intestinal microbiome in type 1 diabetes. Clin Exp Immunol 2014; 177: 30-7.
79. Olivares M, Neef A, Castillejo G et al. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. Gut 2015; 64: 406-17.
80. Nistal E, Caminero A, Herran AR et al. Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. Inflamm Bowel Dis 2012; 18: 649-56.
81. Sellitto M, Bai G, Serena G et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PLoS ONE 2012; 7: e33387.
82. Schippa S, Iebba V, Barbato M et al. A distinctive 'microbial signature' in celiac pediatric patients. BMC Microbiol 2010; 10: 175.
83. Martinez-Martinez RE, Abud-Mendoza C, Patino-Marin N, Rizo-Rodriguez JC, Little JW, Loyola-Rodriguez JP. Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients. J Clin Periodontol 2009; 36: 1004-10.
84. Moen K, Brun JG, Valen M et al. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol 2006; 24: 656-63.
85. Vaahtovuo J, Munukka E, Korkeamaki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol 2008; 35: 1500-5.
86. Scher JU, Sczesnak A, Longman RS et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2013; 2: e01202.
87. Van Praet JT, Donovan E, Vanassche I et al. Commensal microbiota influence systemic autoimmune responses. EMBO J 2015; 34: 466-74.
88. Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357: 1731-43.
89. Rose NR, Bonita R, Burek CL. Iodine: an environmental trigger of thyroiditis. Autoimmun Rev 2002; 1: 97-103.
90. van der Laan JW, Gould S, Tanir JY, Vaccines IH, Adjuvants Safety Project Committee. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine 2015; 33: 1507-14.
91. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012; 12: 127-36.
92. Samuel S, Sitrin MD. Vitamin D's role in cell proliferation and differentiation. Nutr Rev 2008; 66: S116-24.
93. Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013; 45: 256-66.
94. Afridi HI, Kazi TG, Talpur FN, Naher S, Brabazon D. Relationship between toxic metals exposure via cigarette smoking and rheumatoid arthritis. Clin Lab 2014; 60: 1735-45.
95. Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Miettinen A, Julkunen H. Smoking, disease activity, permanent damage and dsDNA autoantibody production in patients with systemic lupus erythematosus. Rheumatol Int 2014; 34: 341-5.
96. Klareskog L, Gregersen PK, Huizinga TW. Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis 2010; 69: 2062-6.
97. Ospelt C, Camici GG, Engler A et al. Smoking induces transcription of the heat shock protein system in the joints. Ann Rheum Dis 2014; 73: 1423-6.
98. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010; 34: J258-65.
99. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008; 30: 5-11.
100. Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME. The consequences of apoptosis in autoimmunity. J Autoimmun 2008; 31: 257-62.
101. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-69.
102. Pieterse E, van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol 2014; 5: 164.
103. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: 202.
104. Lleo A, Bowlus CL, Yang GX et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 2010; 52: 987-98.
105. Vives-Pi M, Rodriguez-Fernandez S, Pujol-Autonell I. How apoptotic beta-cells direct immune response to tolerance or to autoimmune diabetes: a review. Apoptosis 2015; 20: 263-72.
106. Hoffmanova I, Sanchez D, Habova V, Andel M, Tuckova L, Tlaskalova-Hogenova H. Serological markers of enterocyte damage and apoptosis in patients with celiac disease, autoimmune diabetes mellitus and diabetes mellitus type 2. Physiol Res 2014; [Epub ahead of print].
107. Czaja AJ. Targeting apoptosis in autoimmune hepatitis. Dig Dis Sci 2014; 59: 2890-904.
108. Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev 2015; 14: 555-63.
109. Ohishi K, Kanoh M, Shinomiya H, Hitsumoto Y, Utsumi S. Complement activation by cross-linked B cell-membrane IgM. J Immunol 1995; 154: 3173-9.
110. Rodien P, Madec AM, Ruf J et al. Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. J Clin Endocrinol Metab 1996; 81: 2595-600.
111. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010; 9: A259-66.
112. Hewagama A, Gorelik G, Patel D et al. Overexpression of X-linked genes in T cells from women with lupus. J Autoimmun 2013; 41: 60-71.
113. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-50.
114. Han L, Yang J, Wang X, Li D, Lv L, Li B. Th17 cells in autoimmune diseases. Front Med 2015; 9: 10-9.
115. Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun Rev 2015; 14: 105-16.
116. Craft JE. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 2012; 8: 337-47.
117. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 2014; 48-49: 143-8.
118. Gomez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2014; 48-49: 20-5.
119. Hajj-Ali RA, Calabrese LH. Diagnosis and classification of central nervous system vasculitis. J Autoimmun 2014; 48-49: 149-52.
120. Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, Cid MC. Diagnosis and classification of polyarteritis nodosa. J Autoimmun 2014; 48-49: 84-9.
121. Iaccarino L, Ghirardello A, Bettio S et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 2014; 48-49: 122-7.
122. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 2014; 48-49: 134-42.
123. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 2014; 48-49: 14-9.
124. Mahroum N, Mahagna H, Amital H. Diagnosis and classification of adult Still's disease. J Autoimmun 2014; 48-49: 34-7.
125. Maverakis E, Patel F, Kronenberg DG et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. J Autoimmun 2014; 48-49: 60-5.
126. Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun 2014; 48-49: 50-2.
127. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun 2014; 48-49: 99-103.
128. Moutsopoulos HM. Sjogren's syndrome: a forty-year scientific journey. J Autoimmun 2014; 51: 1-9.
129. Nesher G. Polymyalgia rheumatica-diagnosis and classification. J Autoimmun 2014; 48-49: 76-8.
130. Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun 2014; 48-49: 128-33.
131. Sanchez-Manubens J, Bou R, Anton J. Diagnosis and classification of Kawasaki disease. J Autoimmun 2014; 48-49: 113-7.
132. Lleo A, Zhang W, McDonald WH et al. Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 2014; 60: 1314-23.
133. Zhang J, Zhang W, Leung PS et al. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology 2014; 60: 1708-16.
134. Imam MH, Lindor KD. The natural history of primary biliary cirrhosis. Semin Liver Dis 2014; 34: 329-33.
135. Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J Autoimmun 2014; 48-49: 26-30.
136. Bizzaro N. Autoantibodies as predictors of disease: the clinical and experimental evidence. Autoimmun Rev 2007; 6: 325-33.
137. Liaskou E, Hirschfield GM, Gershwin ME. Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol 2014; 36: 553-68.
138. Eilat D. Introduction: mechanisms of tissue injury in autoimmune diseases. Semin Immunopathol 2014; 36: 491-3.
139. Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013; 8: 303-30.
140. Shimoda S, Ishikawa F, Kamihira T et al. Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory. Gastroenterology 2006; 131: 606-18.
141. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis 2014; 34: 265-72.
142. Raczynska J, Habior A, Paczek L, Foroncewicz B, Pawelas A, Mucha K. Primary biliary cirrhosis in the era of liver transplantation. Ann Transplant 2014; 19: 488-93.
143. Zhao M, Liu S, Luo S et al. DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J Autoimmun 2014; 54: 127-36.
144. Bogdanos DP, Smyk DS, Rigopoulou EI et al. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 2012; 38: J156-69.
145. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014; 13: 700-9.
146. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39: 481-97.
147. DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 2006; 23: 857-66.
148. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.
149. Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis 2014; 34: 318-28.
150. Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005; 25: 265-80.
151. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol 2003; 18: 1118-28.
152. Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet 2013; 382: 1433-44.
153. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013; 41: 126-39.
154. Francque S, Vonghia L, Ramon A, Michielsen P. Epidemiology and treatment of autoimmune hepatitis. Hepat Med 2012; 4: 1-10.
155. Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves' disease. Autoimmun Rev 2014; 13: 398-402.
156. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012; 42: 252-65.
157. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn's disease. Autoimmun Rev 2014; 13: 467-71.
158. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54 e42; quiz e30.
159. Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol 2014; 28: 363-72.
160. Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev 2014; 13: 463-6.
161. Kang JY, Kang AH, Green A, Gwee KA, Ho KY. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. Aliment Pharmacol Ther 2013; 38: 226-45.
162. Paul SP, Spray C. Diagnosing coeliac disease in children. Br J Hosp Med 2014; 75: 268-70.
163. Brandao Neto RA, de Carvalho JF. Diagnosis and classification of Addison's disease (autoimmune adrenalitis). Autoimmun Rev 2014; 13: 408-11.
164. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003; 361: 1881-93.
165. Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology 2006; 45: 187-91.
166. Larche MJ. A short review of the pathogenesis of Sjogren's syndrome. Autoimmun Rev 2006; 5: 132-5.
167. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2014; 73: 1151-6.
168. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384: 1878-88.
169. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68.
170. Nasonov E, Soloviev S, Davidson JE et al. The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). Lupus 2014; 23: 213-9.
171. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
172. Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010; 35: 10-4.
173. Sung YK, Cho SK, Choi CB, Bae SC. Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatol Int 2013; 33: 1525-32.
174. Cree BA. Multiple sclerosis genetics. Handb Clin Neurol 2014; 122: 193-209.
175. Picascia A, Grimaldi V, Pignalosa O, De Pascale MR, Schiano C, Napoli C. Epigenetic control of autoimmune diseases: from bench to bedside. Clin Immunol 2015; 157: 1-15.
176. Morran MP, Vonberg A, Khadra A, Pietropaolo M. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med 2015; 42: 42-60.
177. Stankov K, Benc D, Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013; 132: 1112-22.
178. Stefan M, Zhang W, Concepcion E, Yi Z, Tomer Y. DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology. J Autoimmun 2014; 50: 33-7.
179. Chen H, Lan HY, Roukos DH, Cho WC. Application of microRNAs in diabetes mellitus. J Endocrinol 2014; 222: R1-10.
180. Bianchi I, Carbone M, Lleo A, Invernizzi P. Genetics and epigenetics of primary biliary cirrhosis. Semin Liver Dis 2014; 34: 255-64.
181. Tang J, Zhou C, Zhang ZJ, Zheng SS. Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis. Hepatobiliary Pancreat Dis Int 2012; 11: 125-31.
182. Li K, Du Y, Jiang BL, He JF. Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy. Med Sci Monit 2014; 20: 639-43.
183. Wei H, Guan M, Qin Y et al. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy. Endocr J 2014; 61: 1087-92.
184. Cai TT, Muhali FS, Song RH et al. Genome-wide DNA methylation analysis in Graves' disease. Genomics 2015; 105: 204-10.
185. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol 2014; 9: 147-56.
186. Marino M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves' disease. J Endocrinol Invest 2014; [Epub ahead of print]
187. Kalla R, Ventham NT, Kennedy NA et al. MicroRNAs: new players in IBD. Gut 2015; 64: 504-13.
188. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009; 10: 89-116.
189. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999; 45: 395-401.
190. Denizot J, Desrichard A, Agus A et al. Diet-induced hypoxia responsive element demethylation increases CEACAM6 expression, favouring Crohn's disease-associated Escherichia coli colonisation. Gut 2015; 64: 428-37.
191. Adams AT, Kennedy NA, Hansen R et al. Two-stage genome-wide methylation profiling in childhood-onset Crohn's Disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci. Inflamm Bowel Dis 2014; 20: 1784-93.
192. Lv B, Liu Z, Wang S et al. miR-29a promotes intestinal epithelial apoptosis in ulcerative colitis by down-regulating Mcl-1. Int J Clin Exp Pathol 2014; 7: 8542-52.
193. Karatzas PS, Mantzaris GJ, Safioleas M, Gazouli M. DNA methylation profile of genes involved in inflammation and autoimmunity in inflammatory bowel disease. Medicine 2014; 93: e309.
194. Harris RA, Nagy-Szakal D, Mir SA et al. DNA methylation-associated colonic mucosal immune and defense responses in treatment-naive pediatric ulcerative colitis. Epigenetics 2014; 9: 1131-7.
195. Bascunan-Gamboa KA, Araya-Quezada M, Perez-Bravo F. MicroRNAs: an epigenetic tool to study celiac disease. Rev Esp Enferm Dig 2014; 106: 325-33.
196. Lundin KE, Sollid LM. Advances in coeliac disease. Curr Opin Gastroenterol 2014; 30: 154-62.
197. Kaukinen K, Maki M. Coeliac disease in 2013: new insights in dietary-gluten-induced autoimmunity. Nat Rev Gastroenterol Hepatol 2014; 11: 80-2.
198. Fernandez-Jimenez N, Castellanos-Rubio A, Plaza-Izurieta L et al. Coregulation and modulation of NFkappaB-related genes in celiac disease: uncovered aspects of gut mucosal inflammation. Hum Mol Genet 2014; 23: 1298-310.
199. Bernecker C, Halim F, Haase M, Willenberg HS, Ehlers M, Schott M. MicroRNA expressions in PMBCs, CD4+, and CD8+ T-cells from patients suffering from autoimmune Addison's disease. Horm Metab Res 2013; 45: 599-604.
200. Bjanesoy TE, Andreassen BK, Bratland E et al. Altered DNA methylation profile in Norwegian patients with Autoimmune Addison's Disease. Mol Immunol 2014; 59: 208-16.
201. Bronstad I, Wolff AS, Lovas K, Knappskog PM, Husebye ES. Genome-wide copy number variation (CNV) in patients with autoimmune Addison's disease. BMC Med Genet 2011; 12: 111.
202. Gallo A, Tandon M, Illei G, Alevizos I. Discovery and validation of novel microRNAs in Sjogren's syndrome salivary glands. Clin Exp Rheumatol 2014; 32: 761-2.
203. Shi H, Zheng LY, Zhang P, Yu CQ. miR-146a and miR-155 expression in PBMCs from patients with Sjogren's syndrome. J Oral Pathol Med 2014; 43: 792-7.
204. Konsta OD, Thabet Y, Le Dantec C et al. The contribution of epigenetics in Sjogren's Syndrome. Front Genet 2014; 5: 71.
205. Lessard CJ, Li H, Adrianto I et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet 2013; 45: 1284-92.
206. Huang R, Yin J, Chen Y et al. The amino acid variation within the binding pocket 7 and 9 of HLA-DRB1 molecules are associated with primary Sjogren's syndrome. J Autoimmun 2015; 57: 53-9.
207. Guerra SG, Vyse TJ, Cunninghame Graham DS. The genetics of lupus: a functional perspective. Arthritis Res Ther 2012; 14: 211.
208. Miao CG, Yang YY, He X et al. The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal 2013; 25: 1828-36.
209. Zhang Y, Zhang J, Yang J et al. Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus. Hum Mol Genet 2015; 24: 274-84.
210. Deng Y, Tsao BP. Advances in lupus genetics and epigenetics. Curr Opin Rheumatol 2014; 26: 482-92.
211. Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol 2006; 28: 97-107.
212. Bottini N, Firestein GS. Epigenetics in rheumatoid arthritis: a primer for rheumatologists. Curr Rheumatol Rep 2013; 15: 372.
213. Yamamoto K, Okada Y, Suzuki A, Kochi Y. Genetics of rheumatoid arthritis in Asia-present and future. Nat Rev Rheumatol 2015; 11: 375-9.
214. Diogo D, Okada Y, Plenge RM. Genome-wide association studies to advance our understanding of critical cell types and pathways in rheumatoid arthritis: recent findings and challenges. Curr Opin Rheumatol 2014; 26: 85-92.
215. Kochi Y, Suzuki A, Yamamoto K. Genetic basis of rheumatoid arthritis: a current review. Biochem Biophys Res Commun 2014; 452: 254-62.
216. Harkonen T, Lankinen H, Davydova B, Hovi T, Roivainen M. Enterovirus infection can induce immune responses that cross-react with beta-cell autoantigen tyrosine phosphatase IA-2/IAR. J Med Virol 2002; 66: 340-50.
217. Honeyman MC, Stone NL, Falk BA, Nepom G, Harrison LC. Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens. J Immunol 2010; 184: 2204-10.
218. Hiemstra HS, Schloot NC, van Veelen PA et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci USA 2001; 98: 3988-91.
219. Hintermann E, Holdener M, Bayer M et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmun 2011; 37: 242-53.
220. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006; 39: 63-70.
221. Lunemann JD, Huppke P, Roberts S, Bruck W, Gartner J, Munz C. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008; 71: 1033-5.
222. Petersen J, Rhodes G, Roudier J, Vaughan JH. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1990; 33: 993-1000.
223. Rozenblyum EV, Allen UD, Silverman ED, Levy DM. Cytomegalovirus infection in childhood-onset systemic lupus erythematosus. Int J Clin Rheumatol 2013; 8: 137-46.
224. Tucker WG, Andrew Paskauskas R. The MSMV hypothesis: measles virus and multiple sclerosis, etiology and treatment. Med Hypotheses 2008; 71: 682-9.
225. Alidjinou EK, Sane F, Engelmann I, Geenen V, Hober D. Enterovirus persistence as a mechanism in the pathogenesis of type 1 diabetes. Discov Med 2014; 18: 273-82.
226. Andrade F, Casciola-Rosen LA, Rosen A. Generation of novel covalent RNA-protein complexes in cells by ultraviolet B irradiation: implications for autoimmunity. Arthritis Rheum 2005; 52: 1160-70.
227. Cooper GS, Wither J, Bernatsky S et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology 2010; 49: 2172-80.
228. Caricchio R, McPhie L, Cohen PL. Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 2003; 171: 5778-86.
229. Incorvaia E, Sicouri L, Petersen-Mahrt SK, Schmitz KM. Hormones and AID: balancing immunity and autoimmunity. Autoimmunity 2013; 46: 128-37.
230. Shoenfeld Y, Tincani A, Gershwin ME. Sex gender and autoimmunity. J Autoimmun 2012; 38: J71-3.
231. Cojocaru M, Chicos B. The role of heavy metals in autoimmunity. Rom J Intern Med 2014; 52: 189-91.
232. Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
233. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1): S62-9.
234. Lindor KD, Gershwin ME, Poupon R et al. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
235. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
236. Hennes EM, Zeniya M, Czaja AJ et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
237. Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
238. Shoenfeld Y, Cervera R, Gershwin ME. Diagnostic Criteria in Autoimmune Diseases. New Jersey: Springer Science & Business Media, 2010.
239. Van Assche G, Dignass A, Panes J et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
240. Stange EF, Travis SP, Vermeire S et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23.
241. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990; 65: 909-11.
242. Fox RI. Sjogren's syndrome. Lancet 2005; 366: 321-31.
243. Shiboski SC, Shiboski CH, Criswell L et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012; 64: 475-87.
244. Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86.
245. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
246. Rau R. Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother 2014; 15: 1575-83.
247. Flammer JR, Rogatsky I. Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol 2011; 25: 1075-86.
248. Goodin DS. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol 2014; 122: 455-64.
249. Hashkes PJ, Becker ML, Cabral DA et al. Methotrexate: new uses for an old drug. J Pediatr 2014; 164: 231-6.
250. Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013; 368: 1528-35.
251. Invernizzi P, Benedetti MD, Poli S, Monaco S. Azathioprine in multiple sclerosis. Mini Rev Med Chem 2008; 8: 919-26.
252. Louis E, Irving P, Beaugerie L. Use of azathioprine in IBD: modern aspects of an old drug. Gut 2014; 63: 1695-9.
253. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175: 408-18.
254. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
255. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res 2015; 165: 270-82.
256. Song SN, Yoshizaki K. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol 2015; 11: 307-16.
257. Meng Y, Dongmei L, Yanbin P et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol 2014; 39: 696-707.
258. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
259. Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther 2014; 8: 87-100.